Is Adding HCV Screening to the Antenatal National Screening Program in Amsterdam, The Netherlands, Cost-Effective?

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Urbanus, Anouk T ^a,b   van Keep, Marjolijn ^c   Matser, Amy A ^a,d   Rozenbaum, Mark H ^c   Weegink, Christine J ^b   van den Hoek, Anneke ^a,b   Prins, Maria ^a,b   Postma, Maarten J ^c  

^a DEPARTMENT OF INFECTIOUS DISEASES   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF GRONINGEN   (Netherlands)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA; PROTEINASE INHIBITOR; RIBAVIRIN;

ADULT; ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; FEMALE; HEALTH PROGRAM; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMIGRANT; MAJOR CLINICAL STUDY; NETHERLANDS; PREGNANT WOMAN; PRENATAL DIAGNOSIS; PREVALENCE; RETROSPECTIVE STUDY; STATISTICAL PARAMETERS;

ADULT; AGED; AGED, 80 AND OVER; COST-BENEFIT ANALYSIS; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; MARKOV CHAINS; MASS SCREENING; MIDDLE AGED; MODELS, STATISTICAL; NETHERLANDS; PREGNANCY; PRENATAL DIAGNOSIS; YOUNG ADULT;

EID: 84881490794     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0070319     Document Type: Article

References (32)

1. Alter MJ, (2002) Prevention of spread of hepatitis C. Hepatology 36: S93-S98.
2. Shepard CW, Finelli L, Alter MJ, (2005) Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 5: 558-567.
3. Vriend HJ, van Veen MG, Prins M, Urbanus AT, Boot HJ, et al. (2012) Hepatitis C virus prevalence in The Netherlands: migrants account for most infections. Epidemiol Infect pp. 1-8.
4. Helsper CW, Borkent-Raven BA, de Wit NJ, van Essen GA, Bonten MJ, et al. (2011) Cost-effectiveness of targeted screening for hepatitis C in The Netherlands. Epidemiol Infect pp. 1-12.
5. Lindenburg CE, Lambers FA, Urbanus AT, Schinkel J, Jansen PL, et al. (2011) Hepatitis C testing and treatment among active drug users in Amsterdam: results from the DUTCH-C project. Eur J Gastroenterol Hepatol 23: 23-31.
6. Zuure FR, Davidovich U, Coutinho RA, Kok G, Hoebe CJ, et al. (2011) Using mass media and the Internet as tools to diagnose hepatitis C infections in the general population. Am J Prev Med 40: 345-352.
7. Urbanus AT, van de Laar TJW, van den Hoek A, Zuure FR, Speksnijder AGCL, et al. (2011) Hepatitis C in the general population of various ethnic origins living in the Netherlands: should non-Western migrants be screened? Journal of Hepatology doi:10 1016/j jhep 2011 02 028. In press.
8. Indolfi G, Resti M, (2009) Perinatal transmission of hepatitis C virus infection. J Med Virol 81: 836-843.
9. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, et al. (2011) Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 364: 2405-2416.
10. Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, et al. (2011) Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 364: 1195-1206.
11. Sroczynski G, Esteban E, Conrads-Frank A, Schwarzer R, Muhlberger N, et al. (2009) Long-term effectiveness and cost-effectiveness of screening for hepatitis C virus infection. Eur J Public Health 19: 245-253.
12. Plunkett BA, Grobman WA, (2005) Routine hepatitis C virus screening in pregnancy: a cost-effectiveness analysis. Am J Obstet Gynecol 192: 1153-1161.
13. van der Bij AK, Mulder-Folkerts DK, van den Hoek JA, Boer K, Schutte MF, et al. (2003) [HIV-screening among pregnant women in the region of Amsterdam in 2002]. Ned Tijdschr Geneeskd 147: 1232-1236.
14. Rozenbaum MH, Sanders EA, van Hoek AJ, Jansen AG, van der Ende A, et al. (2010) Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines. BMJ 340: c2509.
15. Urbanus AT, van de Laar TJ, van den Hoek A, Zuure FR, Speksnijder AG, et al. (2011) Hepatitis C in the general population of various ethnic origins living in the Netherlands: Should non-Western migrants be screened? J Hepatol.
16. Micallef JM, Kaldor JM, Dore GJ, (2006) Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat 13: 34-41.
17. Briggs A, Claxton K, Sculpher M (2008) Decision modelling for health economic evaluation. Oxford University Press.
18. Deuffic-Burban S, Wong JB, Valleron AJ, Costagliola D, Delfraissy JF, et al. (2004) Comparing the public health burden of chronic hepatitis C and HIV infection in France. J Hepatol 40: 319-326.
19. Sroczynski G, Esteban E, Conrads-Frank A, Schwarzer R, Muhlberger N, et al. (2010) Long-term effectiveness and cost-effectiveness of antiviral treatment in hepatitis C. J Viral Hepat 17: 34-50.
20. Sroczynski G, Esteban E, Conrads-Frank A, Schwarzer R, Muhlberger N, et al. (2009) Long-term effectiveness and cost-effectiveness of screening for hepatitis C virus infection. Eur J Public Health 19: 245-253.
21. Miners A, Ghosh A, Martin N, Vickerman P, (2012) An economic evaluation of finding cases of hepatitis B and C infection in UK migrant populations, Faculty of Public Health and Policy, London School of Hygiene and tropical Medicine.
22. Wong VW, Chan FK, (2012) A new era of hepatitis C treatment. Gastroenterology 143: 264-265.
23. Siebert U, Sroczynski G, Rossol S, Wasem J, Ravens-Sieberer U, et al. (2003) Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C. Gut 52: 425-432.
24. Op DE, Coul EL, Hahne S, van Weert YW, Oomen P, et al. (2011) Antenatal screening for HIV, hepatitis B and syphilis in the Netherlands is effective. BMC Infect Dis 11: 185.
25. Zuure FR, Davidovich U, Coutinho RA, Kok G, Hoebe CJ, et al. (2011) Using mass media and the Internet as tools to diagnose hepatitis C infections in the general population. Am J Prev Med 40: 345-352.
26. Cooper C, (2012) Hepatitis C treatment highlights from the 2011 American Association for the Study of Liver Disease meeting. Clin Infect Dis 55: 418-425.
27. Shepherd J, Jones J, Hartwell D, Davidson P, Price A, et al. (2007) Interferon alpha (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation. Health Technol Assess 11: 1-iii, 1-205, iii.
28. Wong JB, Poynard T, Ling MH, Albrecht JK, Pauker SG, (2000) Cost-effectiveness of 24 or 48 weeks of interferon alpha-2b alone or with ribavirin as initial treatment of chronic hepatitis C. International Hepatitis Interventional Therapy Group. Am J Gastroenterol 95: 1524-1530.
29. Statistics Netherlands (2012) Mortality rates. Available: http://statline.cbs.nl/StatWeb/publication/default.aspx?DM=SLNL&PA=37530NED&D1=1&D2=a&D3=0&D4=l&HDR=T%2cG1&STB=G2%2cG3&VW=T.
30. College voor Zorgverzekeringen. Available: www.medicijnkosten.nl. Accesed 2012 Aug 3.
31. Helsper CW, Hellinga HL, van Essen GA, de Wit GA, Bonten MJ, et al. (2012) Real-life costs of hepatitis C treatment. Neth J Med 70: 145-153.
32. Singer ME, Younossi ZM, (2001) Cost effectiveness of screening for hepatitis C virus in asymptomatic, average-risk adults. Am J Med 111: 614-621.